Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615563 · ClinicalTrials.gov registry record
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 246
- Enrollment target
NCT00615563: Completed study, sponsored by Boehringer Ingelheim.
NCT00615563 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00615563 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
Study Summary
The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.
Interventions
- BEHAVIORAL NO BI Drug administered
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-01 |
What the finished NCT00615563 record still lists
NCT00615563 is an observational study that tracks outcomes without assigning an intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which NO BI Drug administered is the first listed.
NCT00615563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00615563 about?
NCT00615563 is a clinical study titled "Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)". The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently fai...
What is the current status of trial NCT00615563?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2007-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00615563?
The interventions under investigation include: NO BI Drug administered (BEHAVIORAL).
Who is sponsoring clinical trial NCT00615563?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia